Phase I/II trial of a COX-2 inhibitor with limited field radiation for intermediate prognosis patients who have locally advanced non–small-cell lung cancer: radiation …
E Gore, K Bae, C Langer, M Extermann, B Movsas… - Clinical lung cancer, 2011 - Elsevier
Background Treatment of patients who have locally advanced non–small-cell lung cancer
and compromised performance status or weight loss (WL) is challenging. This study was …
and compromised performance status or weight loss (WL) is challenging. This study was …
Celecoxib and bevacizumab synergistically inhibit non-small cell lung cancer by inducing apoptosis and modulating VEGF and MMP-9 expression.
A Qadir, Z Khalid, FK Theba, MM Ali… - Pakistan Journal of …, 2023 - search.ebscohost.com
Lung cancer is the most typical form of cancer that results in death worldwide. Patients with
non-small cell lung cancer (NSCLC) have an around 15% survival rate despite of …
non-small cell lung cancer (NSCLC) have an around 15% survival rate despite of …
[HTML][HTML] Dimethyl celecoxib as a novel non–cyclooxygenase 2 therapy in the treatment of non–small cell lung cancer
OBJECTIVES: The cyclooxygenase 2 enzyme has become a therapeutic target in cancer
treatment. Cyclooxygenase 2 blockade with selective inhibitors increases apoptosis and …
treatment. Cyclooxygenase 2 blockade with selective inhibitors increases apoptosis and …
Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study
L Chen, Y He, H Huang, H Liao, W Wei - Medical Oncology, 2008 - Springer
Constitutive expression of cyclooxygenase-2 (COX-2) and epidermal growth factor receptor
(EGFR) occurs frequently in non-small cell lung cancer (NSCLC). Anticancer research …
(EGFR) occurs frequently in non-small cell lung cancer (NSCLC). Anticancer research …
Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non–small-cell lung cancer
KJ O'Byrne, S Danson, D Dunlop, N Botwood… - Journal of clinical …, 2007 - ascopubs.org
Purpose In non–small-cell lung cancer (NSCLC), the epidermal growth factor receptor
(EGFR) and cyclooxygenase-2 (COX-2) play major roles in tumorigenesis. This phase I/II …
(EGFR) and cyclooxygenase-2 (COX-2) play major roles in tumorigenesis. This phase I/II …
Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non–small-cell lung cancer
NK Altorki, RS Keresztes, JL Port, DM Libby… - Journal of clinical …, 2003 - ascopubs.org
Purpose: Preclinical studies suggest that treatment with a selective cyclo-oxygenase-2 (COX-
2) inhibitor may augment the antitumor effects of chemotherapy. In this study, patients with …
2) inhibitor may augment the antitumor effects of chemotherapy. In this study, patients with …
Effect of concurrent chemoradiation with celecoxib vs concurrent chemoradiation alone on survival among patients with non–small cell lung cancer with and without …
N Bi, J Liang, Z Zhou, D Chen, Z Fu, X Yang… - JAMA Network …, 2019 - jamanetwork.com
Importance Treatment of locally advanced non–small cell lung cancer (NSCLC) remains
challenging. The rationale of combining a cyclooxygenase 2 (COX-2) inhibitor with …
challenging. The rationale of combining a cyclooxygenase 2 (COX-2) inhibitor with …
COX-2 inhibitors, a potential synergistic effect with antineoplastic drugs in lung cancer
W Hohenforst-Schmidt, K Domvri, N Zogas… - Oncomedicine, 2017 - oncm.org
Background: Lung cancer represents the leading cause of cancer-related deaths worldwide
and novel therapeutic approaches targeting crucial pathways are urgently needed to …
and novel therapeutic approaches targeting crucial pathways are urgently needed to …
Gastrointestinal hemorrhage in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib and celecoxib
7172 Background: Erlotinib (E) was associated with superior survival in a phase III trial of
previously treated advanced NSCLC patients (pts). Celecoxib (C) has been shown to …
previously treated advanced NSCLC patients (pts). Celecoxib (C) has been shown to …
Cyclooxygenase 2 inhibition in patients with non–small cell lung cancer: Is this still a valid target for therapy?
SM Gadgeel - Cancer, 2015 - Wiley Online Library
In a randomized trial, the combination of the cyclooxygenase 2 (COX‐2) inhibitor celecoxib
with erlotinib demonstrated improved progression‐free survival in patients with elevated …
with erlotinib demonstrated improved progression‐free survival in patients with elevated …